Key Market Indicators
Chinese pharmaceutical research and development (R&D) expenditure is projected to soar to $48.7 billion by 2028, according to recent data. This marks a significant increase from the $30.2 billion forecasted for 2023, reflecting an annual growth rate of 7.5%. Since 2013, China has consistently ramped up its R&D investments, with an average annual increase of 17.1%. In 2023, China held the second spot globally in pharmaceutical R&D expenditure, trailing only the United States, which also posted expenditures of $30.2 billion. Germany and South Korea followed China, ranking third and fourth respectively in global pharmaceutical R&D spending. The continued investment underscores China's commitment to advancing its capabilities in the pharmaceutical sector.
